![]() |
Search Options | |||
Index | Site Map | FAQ | Facility Info | Reading Rm | New | Help | Glossary | Contact Us | ![]() |
POLICY ISSUE SECY-01-0069 April 24, 2001
To provide to the Commission revised draft NUREG-1633 (Attachment
1 On December 22, 2000, the Commission approved a final rule amending 10
CFR 50.47(b)(10) to require that consideration be given to including
the prophylactic use of potassium iodide (KI) as a protective measure
for the general public in the plume exposure pathway. The final rule was
published in the Federal Register on January 19, 2001 (66 FR
5427) with an effective date of April 19, 2001. Staff Requirements Memorandum
(SRM), dated December 22, 2000, states that the Commission will fund State
stockpiles of KI and work with the Federal Emergency Management Agency
(FEMA There are three principal activities associated with implementing the Commission's decision on KI. They are (1) preparation of revised draft NUREG-1633, "Assessment of the Use of Potassium Iodide as a Supplemental Public Protective Action During a Severe Reactor Accident"; (2) development and implementation of a KI tablet/funding program; and (3) publication of revised federal policy on the use of KI. The status of each of these activities is discussed below.
In SRM, COMSECY-98-016, issued on September 30, 1998, the Commission directed the staff to withdraw the existing draft version of NUREG-1633, and to reissue a substantially revised document taking public comments into account and making the following changes:
The revised draft NUREG forwarded with this paper for Commission approval to be published for public comment, presents information that State and local decision makers could use to (1) decide whether KI should be incorporated into their current offsite emergency response plans; and (2) determine the best method to distribute KI to members of the public living within the 10-mile emergency planning zone (EPZ) of nuclear power plants. To this end, the staff considered the public comments and the comments of the 'KI Core Group', as well as the direction provided in COMSECY-98-016 and SRM dated December 22, 2000, in preparing the revised draft NUREG-1633. The revised draft discusses various aspects of the use of KI during nuclear power plant emergencies. The revised draft also contains direct input from those States that have KI as a supplemental protective action (Alabama, Tennessee, Arizona and New Hampshire). These States detailed the experiences they have had in the implementation as well as KI distribution phases of their programs. The international community also provided input on the programs that they have in place. The revised draft FDA guidance is also included in its entirety as a chapter within revised NUREG-1633. The comment period on the draft FDA guidance ends on April 27, 2001. Revised NUREG-1633 relies heavily upon findings as presented in the draft FDA guidance. Should the FDA guidance change as a result of the public comments received, then the appropriate changes would also be made in NUREG-1633. The WHO recommendations are included in an appendix to provide an international perspective on the use of KI. The IAEA guidance document has not been published in final form and therefore was not included in the NUREG.
The NRC/FEMA Steering Committee co-chairs met on January 29, 2001 to
discuss the expectations of the Commission on the implementation of a
KI program as outlined in SRM dated December 22, 2000. At this meeting,
it was determined that a KI subcommittee would be appointed, under the
auspices of the NRC/FEMA Steering Committee, with staff from NRC and FEMA
participating. Office of Nuclear Reactor Regulation (NRR) staff met with
the Office of the General Counsel (OGC) on February 14, 2001 to request
that an appropriately worded disclaimer, per the SRM and the Statements
of Consideration (SOC) Issue H, be developed. OGC has drafted a proposed
disclaimer which is attached (Attachment
3 A teleconference with the KI subcommittee was held on February 16, 2001,
to discuss the SRM, proposed federal policy on KI, as well as the final
rule SOC. The subcommittee met on February 27, 2001 to develop a charter
and task list and discuss an implementation plan (Attachment
4 NRC/FEMA staff roles and responsibilities for the KI program and a milestone schedule for program implementation are under development by the KI subcommittee and will be finalized pending the completion of FEMA staff's brief of their new Director. The subcommittee has developed three proposed application processes as well as three distribution options. These options are provided for information and are discussed below. The subcommittee decided that, while local governments may be designated by the States to request KI, all requests for KI should come through the appropriate State or Tribal government. An application form detailing the State's request for KI will be developed. The options are presented in the current order of preference of the KI subcommittee. The options detailing the application process assume NRC management of funds.
These options will be presented to the NRC/FEMA Steering Committee for their consideration and recommendations. The staff is developing a KI website to keep interested parties informed
of the program development and subsequent implementation (Attachment
6 The staff met with the Office of Administration (ADM) contract specialist on March 9, 2001, to discuss various purchase options for KI, including bulk purchase of KI tablets, with direct shipment to the requesting states. The staff will continue to work with ADM to evaluate cost-effective options for purchase of KI tablets. The staff has briefed the Office of Public Affairs (OPA) and the staff is working with OPA on answers to likely questions from the interested parties about the rulemaking, KI, and the implementation program. The Office of State and Tribal Programs (STP) was briefed during their regional counterpart meeting with State Liaison Officers. Representatives of NRR attended and made a presentation on KI, as well as participated in a panel on KI with FEMA and FDA, at the National Radiological Emergency Preparedness Conference held in Nashville, TN on April 2-5, 2001. Additionally, the staff regularly provides updates for the Chairman's Tasking Memorandum milestone schedule. The next meeting of the KI subcommittee is scheduled for April 18, 2001 to continue development and implementation of the KI program. The NRC/FEMA Steering Committee will be briefed and provided the application and distribution options and the milestone schedule for their consideration and recommendations at their next meeting in June 2001.
The staff presented the Commission's recommended revision of the KI Federal Policy to the Federal Radiological Preparedness Coordinating Committee (FRPCC) for review and comment on January 17, 2001. FRPCC member agencies were requested to review the draft and provide comments to FEMA by February 16, 2001. As of the due date, FEMA had received comments from only two agencies. The staff participated in an FRPCC retreat held on March 7-8, 2001. At this retreat, the NRC staff requested a commitment from the FRPCC on timely approval of the Federal KI Policy. The FRPCC Chair committed to conduct a vote on approval of the draft Federal KI Policy at the next FRPCC meeting scheduled for May 8, 2001. However, the policy is still under review by FEMA. When FEMA sends its formal comments to the NRC, the staff will forward them to the Commission for its review and approval. FEMA has recognized that a special meeting of the FRPCC may need to be convened if the May 8 vote cannot be realized due to a delay in forwarding the comments to the NRC. The staff has followed the Commission's direction provided in COMSECY-98-016 and SRM dated December 22, 2000, in preparing the revised draft NUREG-1633 forwarded with this paper for Commission approval for publication for public comment. The issuance of NUREG-1633 as a final document and the implementation of the KI program is dependent upon the issuance of FDA's final guidance on the use of KI. The comment period on the draft FDA guidance was extended from February 4, 2001 until April 27, 2001. It is unknown at this time, when the final guidance will be issued. The FDA's final guidance may impact draft NUREG-1633, which would need to be revised prior to publication, to accommodate any FDA guidance changes. The staff intends to develop a program structure to enable timely implementation of the program when the final FDA guidance is released. That the Commission approve the staff recommendation to publish draft NUREG-1633 for a 60-day public comment period. The Office of the General Counsel has reviewed this paper, as well as draft NUREG-1633, and has no legal objection.
|
Privacy Policy |
Site Disclaimer |